<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26631" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Paraneoplastic Encephalomyelitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tirthani</surname>
            <given-names>Ekta</given-names>
          </name>
          <aff>Rochester General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Said</surname>
            <given-names>Mina S.</given-names>
          </name>
          <aff>Rochester General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Robert G.</given-names>
          </name>
          <aff>Houston Methodist Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jadhav</surname>
            <given-names>Nagesh</given-names>
          </name>
          <aff>Rochester General Hospital and University of Rochester</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shanina</surname>
            <given-names>Elena</given-names>
          </name>
          <aff>University of Texas Medical Branch</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ekta Tirthani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mina Said declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nagesh Jadhav declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elena Shanina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26631.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Paraneoplastic Encephalomyelitis is a subtype of paraneoplastic neurological syndromes. This group of neurological disorders is associated with antibodies against intracellular and extracellular neuronal proteins related to cancer, involving focal or multifocal inflammation of the brain, spinal cord, or both. This article describes the pathophysiology, clinical features, diagnostic approach, and management of paraneoplastic encephalomyelitis and highlights the role of the interprofessional team in evaluating and treating patients to avoid high morbidity and mortality associated with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarise the etiology of paraneoplastic encephalomyelitis.</p></list-item><list-item><p>Describe different clinical manifestations of paraneoplastic encephalomyelitis.</p></list-item><list-item><p>Summarize the treatment options available for paraneoplastic encephalomyelitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26631&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26631">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26631.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Paraneoplastic encephalomyelitis (PEM) is a subtype of paraneoplastic neurological syndromes (PNS), a group of neurological manifestations associated with antibodies against intracellular and extracellular neuronal proteins that are invariably cancer-related, involving focal or multifocal inflammation of the brain or spinal cord or both.<xref ref-type="bibr" rid="article-26631.r1">[1]</xref><xref ref-type="bibr" rid="article-26631.r2">[2]</xref></p>
        <p>The definite diagnosis of paraneoplastic neurological syndromes, per the 2004 definition, encompasses:</p>
        <list list-type="order">
          <list-item>
            <p>A classical syndrome (includes encephalomyelitis, limbic encephalitis, subacute cerebellar degeneration, and opsoclonus-myoclonus) and cancer develops within 5 years of diagnosis of the neurological disorder.</p>
          </list-item>
          <list-item>
            <p>A non-classical neurological syndrome is one that resolves or significantly improves after cancer treatment, without immunotherapy.</p>
          </list-item>
          <list-item>
            <p>A non-classical neurological syndrome with paraneoplastic antibodies and cancer develops within 5 years of the diagnosis of the neurological disorder.<xref ref-type="bibr" rid="article-26631.r3">[3]</xref><xref ref-type="bibr" rid="article-26631.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>Paraneoplastic encephalomyelitis&#x000a0;typically&#x000a0;involves B-cell activation, with the production of autoantibodies that identify immune marker&#x000a0;disease subtypes.&#x000a0; Originally thought to be totally separable from primary autoimmune disease, paraneoplastic antibody markers are now thought to be of three types:</p>
        <p>- Autoantibodies targeting intracellular epitopes thought to cross-react between cancer and central nervous system proteins, glycoproteins, and complex carbohydrates.&#x000a0;Associated diseases can include limbic encephalitis, encephalomyelitis, subacute cerebellar degeneration, opsoclonus myoclonus, optic neuritis, and rapidly progressive sensory polyneuropathy. &#x000a0;These antibodies are&#x000a0;not pathogenic in the classical sense. Patients do not usually respond to standard immunomodulatory therapies when these are the sole immune targets identified in the paraneoplastic process. Their function is just now being elucidated as providing targets for cytotoxic T cell infiltration into tumor and non-neoplastic cells with cross-reactive intracellular epitopes, the latter producing bystander destruction and paraneoplastic syndromes (for review, see).<xref ref-type="bibr" rid="article-26631.r5">[5]</xref> &#x000a0;&#x000a0;Understanding the mechanism of such intracellular antibody targeting against intracellular tumor antigens may eventually provide an effective cancer therapeutics method.<xref ref-type="bibr" rid="article-26631.r6">[6]</xref></p>
        <p>- Autoantibodies targeting intracellular epitopes at synaptic sites, producing potentially treatable conditions.&#x000a0; Diseases like progressive encephalomyelitis with rigidity and myoclonus (PERM), stiff person syndrome, and cerebellar ataxia have been linked to such antibodies, and passive transfer of such intracellular epitope targeted antibodies from patients to na&#x000ef;ve animal models can reproduce symptoms of the disease.<xref ref-type="bibr" rid="article-26631.r7">[7]</xref></p>
        <p>- Autoantibodies targeting extracellular epitopes that directly cause neurologic dysfunction.&#x000a0; These autoantibodies were originally identified in non-paraneoplastic autoimmune disease, can be suppressed by antibody depleting or blocking therapies, and are often recognized as the first cancer evidence. Diseases produced by such antibodies include paraneoplastic myasthenia gravis, Lambert Eaton myasthenic syndrome, limbic encephalitis, encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody-associated disease, and neuromyelitis optica spectrum disorder, among others.&#x000a0; &#x000a0;Recognizing the evolving concepts surrounding paraneoplastic and non-paraneoplastic autoimmune CNS disease has helped identify and treat these disorders.<xref ref-type="bibr" rid="article-26631.r8">[8]</xref></p>
        <p>There is overlap between traditional paraneoplastic disorders and extracellular epitope associated autoimmune encephalitides, a group of syndromes associated with autoantibodies against extracellular neuronal cell surface proteins, synaptic proteins, ion channels, or receptors, usually most common in the non-paraneoplastic disease.<xref ref-type="bibr" rid="article-26631.r9">[9]</xref><xref ref-type="bibr" rid="article-26631.r10">[10]</xref>&#x000a0; This is especially important in the era of cancer chemotherapy with checkpoint inhibitors. The incidence of immunological toxicity is much higher with these therapies than in traditional cancer chemotherapy, producing immune-related adverse events that may present as paraneoplastic neurologic syndromes.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref><xref ref-type="bibr" rid="article-26631.r12">[12]</xref>&#x000a0; Recognizing which antibody targets are important in secondary immune disease production and which paraneoplastic antibodies are not amenable to immunomodulatory therapy is important for treatment decisions.<xref ref-type="bibr" rid="article-26631.r5">[5]</xref></p>
      </sec>
      <sec id="article-26631.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>As the name entails, paraneoplastic encephalomyelitis is associated with the presence of cancer, especially prevalent in small cell lung cancer (SCLC), in addition to breast cancer, testicular cancer, gynecologic cancers, and Hodgkin&#x02019;s lymphoma.<xref ref-type="bibr" rid="article-26631.r13">[13]</xref></p>
        <p>Immune checkpoint inhibitors are believed to unleash paraneoplastic neurological syndromes as well, more frequently with anti-PD1 agents eg. pembrolizumab, nivolumab, and cemiplimab.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref></p>
      </sec>
      <sec id="article-26631.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The true incidence of paraneoplastic syndromes is unknown, though older reports or those limiting assessment to classic immune antibody markers describe an incidence of paraneoplastic disease as 1 in 10,000 cases of malignancy (0.01%),&#x000a0;with paraneoplastic neurological syndromes having an incidence of 0.86 per 100,000 and prevalence of 4.37 per 100,000 cases.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref><xref ref-type="bibr" rid="article-26631.r14">[14]</xref><xref ref-type="bibr" rid="article-26631.r15">[15]</xref>&#x000a0;However, in carefully reviewed patients in a specialized center, reported incidence of PNS was much higher, approaching an incidence of 0.25% of reviewed cases.&#x000a0; Therefore, as newer technologies are developed to identify immune responses to cancer, we may expect the reported incidence and prevalence of paraneoplastic processes to increase.</p>
        <p>Paraneoplastic Encephalomyelitis (PEM) constitutes 10% of all encephalomyelitis cases.<xref ref-type="bibr" rid="article-26631.r16">[16]</xref>&#x000a0;Small cell lung cancer is the malignancy associated with PEM in 75% of cases.<xref ref-type="bibr" rid="article-26631.r17">[17]</xref></p>
      </sec>
      <sec id="article-26631.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Ectopically presented antigens on the tumor cells that are otherwise exclusively expressed in neurons are presumably the triggers for paraneoplastic encephalitis. Postulated mechanisms of these abnormally expressed antigens include tumor genetic alterations, gene amplification, and protein overexpression. Also, some of these so-called onconeural antigens are normally expressed in immunologically privileged sites like the testes, but for unknown reasons, they get identified by the immune system as foreign, which in turn mounts an immune attack.</p>
        <p>Antigen-presenting cells then activate antigen-specific cytotoxic T cells against neuronal structures, which in turn activate B cells to turn into plasma cells that produce the detectable antibodies. It is the parenchymal invasion of the cytotoxic T cells that leads to neuronal cell damage. As mentioned earlier, the antibodies are directed to intracellular antigens, therefore, cannot cause the disease directly but simply serve as a valuable marker for the underlying tumor, e.g. Anti-Yo antibodies in patients with paraneoplastic cerebellar degeneration are characteristically associated with ovarian cancer.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref><xref ref-type="bibr" rid="article-26631.r14">[14]</xref></p>
        <p>Interestingly, it was shown that this same immune attack sometimes limits the growth of cancer itself and may rarely stop it.<xref ref-type="bibr" rid="article-26631.r18">[18]</xref>&#x000a0;The histological features of tumors in paraneoplastic neurological disorders do not differ from those of other tumors, except that the tumors may be heavily infiltrated with inflammatory cells.<xref ref-type="bibr" rid="article-26631.r16">[16]</xref></p>
        <p>In addition, immune checkpoint blockers may trigger a similar cytotoxic T cell-mediated immune attack, which can cause adverse effects, including limbic encephalitis.<xref ref-type="bibr" rid="article-26631.r19">[19]</xref></p>
        <p>Most commonly, PEM is associated with the Anti-Hu antibody, which is also called ANNA-1 (Anti-Neuronal Nuclear Antibody type 1). Sometimes, it is associated with Anti-CRMP5 (Collapsin Response Mediator Protein 5). Other times, the associated antibodies are the Anti-Amphiphysin.<xref ref-type="bibr" rid="article-26631.r16">[16]</xref></p>
        <table-wrap id="article-26631.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Common paraneoplastic antibodies with their respective associated tumors and clinical presentations.[13][20][21][22][23][5][24]&#x000a0;SCLC- small cell lung carcinoma; PERM- Progressive encephalomyelitis with rigidity and myoclonus;&#x000a0; NMOSD-Neuromyelitis optica spectrum disorders.</title>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Antibody</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Associated tumor</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Clinical Presentation</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Antibodies targeting intracellular epitopes</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Hu (ANNA-1)</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Lung, genitourinary cancer, neuroendocrine tumors</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis, encephalomyelitis, brainstem encephalitis, peripheral neuropathy&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">CRMP5/CV2</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Ling, breast cancer, thymoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Encephalomyelitis, myelitis, cerebellar ataxia, chorea</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Yo (PCA-1)</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Breast, ovarian cancer</p>
</td>
                <td rowspan="1" colspan="1">
<p>Cerebellar ataxia</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Ri (ANNA-2)</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Breast, lung, gynecological cancer</p>
</td>
                <td rowspan="1" colspan="1">
<p>Brainstem encephalitis, cerebellar ataxia, opsoclonus-myoclonus, dystonia</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Tr (DNER)</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Hodgkin lymphoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Cerebellar ataxia, opsoclonus-myoclonus</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Ma</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Testicular Gem Cell tumors</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis, brainstem encephalitis, parkinsonism</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">PCA2</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>SCLC</p>
</td>
                <td rowspan="1" colspan="1">
<p>Cerebellar ataxia, brainstem encephalitis, limbic encephalitis, peripheral neuropathy</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">ROCK2</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Urogenital</p>
</td>
                <td rowspan="1" colspan="1">
<p>Encephalitis, Seizures</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">KLH11</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Testicular Gem Cell tumors</p>
</td>
                <td rowspan="1" colspan="1">
<p>Brainstem encephalitis, limbic encephalitis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Antibodies targeting intracellular synaptic antigens</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">GAD65</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Thymoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Stiff person syndrome, PERM, cerebellar ataxia</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Amphiphysin</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Breast, lung cancer</p>
</td>
                <td rowspan="1" colspan="1">
<p>Stiff person syndrome, PERM, encephalomyelitis, isolated myelopathy, cerebellar ataxia, peripheral neuropathy</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Antibodies targeting extracellular epitopes/cell membrane</bold>&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">NMDAR</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Teratoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">AMPAR</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Lung, breast cancer, thymoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis, dysautonomia</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">LGI1</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Lung cancer, thymoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">CASPR2</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Thymoma, Lung cancer</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis, opsoclonus-myoclonus-ataxia syndrome, neuromyotonia,</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">GABA</italic></bold><bold><italic toggle="yes">B</italic></bold><bold><italic toggle="yes">R</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>SCLC</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis, seizures</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">GABA</italic></bold><bold><italic toggle="yes">A</italic></bold><bold><italic toggle="yes">R</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Thymoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Encephalitis, status epilepticus</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">mGluR1</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Hodgkin lymphoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Cerebellar ataxia</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">GlyR</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Thymoma, Hodgkin lymphoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>PERM</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">mGluR5</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Hodgkin lymphoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>Limbic encephalitis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">AQP4</italic></bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Breast, lung, urogenital thyroid cancer, thymoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>NMOSD</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-26631.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In classic PEM, the pathology involves extensive CNS neuronal destruction, inflammation with T cell infiltrates perivascular B cells, intra-neuronal deposits of antibodies, gliosis, and neuronophagic nodules.<xref ref-type="bibr" rid="article-26631.r14">[14]</xref>&#x000a0;Paraneoplastic encephalomyelitis produced by extracellular targeted antibodies does not produce this type of cellular injury. In the case of NMDAR antibody-associated disease, brain pathology results from an antibody-targeted immune response.<xref ref-type="bibr" rid="article-26631.r25">[25]</xref><xref ref-type="bibr" rid="article-26631.r26">[26]</xref>&#x000a0;Such subtle pathology may be difficult to identify as caused by paraneoplastic disease without the appropriate clinical history.</p>
      </sec>
      <sec id="article-26631.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In general, neurological symptoms often manifest weeks to months before recognition of the tumor in at least 80% of PEM cases.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref>&#x000a0;Onset and progression are usually acute or subacute&#x000a0;rather than insidious.</p>
        <p>Any part of the nervous system can be affected by paraneoplastic disorders:</p>
        <list list-type="bullet">
          <list-item>
            <p>Single cell-type involvement eg. Cerebellar Purkinje cells</p>
          </list-item>
          <list-item>
            <p>Single area involvement eg. Limbic encephalitis</p>
          </list-item>
          <list-item>
            <p>Multi-level involvement eg. Encephalomyelitis, is the main focus of this article.<xref ref-type="bibr" rid="article-26631.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>All assessments should begin with a careful history, focusing on the patient&#x02019;s neurological complaints, the time-course of symptom complex onset and rate of progression, and more general questions that might suggest the presence of an oncologic process. &#x000a0;A family member or multiple patient contacts might need to be questioned to obtain this history in cognitively impaired patients.</p>
        <p>In paraneoplastic encephalomyelitis, there is widespread neural dysfunction, involving symptoms from at least two or more regions, such as the temporal lobes, limbic areas, brainstem, cerebellum, spinal cord, dorsal root ganglia, and the autonomic nervous system. The clinical presentation therefore widely varies depending&#x000a0;on the neural axis components affected, which can manifest as a relatively isolated syndrome, a multifocal process, or a more generalized syndrome involving widespread CNS regions.<xref ref-type="bibr" rid="article-26631.r14">[14]</xref><xref ref-type="bibr" rid="article-26631.r17">[17]</xref><xref ref-type="bibr" rid="article-26631.r27">[27]</xref><xref ref-type="bibr" rid="article-26631.r28">[28]</xref></p>
        <list list-type="order">
          <list-item>
            <p><bold>Paraneoplastic Limbic Encephalitis (PLE)</bold> which predominates in 20% of cases of PEM, affects the hippocampus, hypothalamus, and amygdala. Patients often present with cognitive impairment, personality change, short-term memory loss, mood changes, behavioral changes, and temporal seizures.<xref ref-type="bibr" rid="article-26631.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Paraneoplastic Brainstem Encephalitis / Rhombencephalitis</bold> develops in around 30% of cases of PEM and can occur as an isolated clinical syndrome affecting the brainstem or more often is a part of widespread encephalomyelitis. It can present with the involvement of 1 or more cranial nerves in the pons and medulla with trismus, horizontal conjugate gaze palsy, extraocular movement deficits, opsoclonus, nystagmus, dysphagia, dysarthria, sensorineural deafness, central hypoventilation, and vertigo. Anti-Hu antibodies are more linked with the lower brainstem, while Anti-Ma2 antibodies are commonly associated with upper brainstem involvement.<xref ref-type="bibr" rid="article-26631.r17">[17]</xref><xref ref-type="bibr" rid="article-26631.r29">[29]</xref><xref ref-type="bibr" rid="article-26631.r30">[30]</xref><xref ref-type="bibr" rid="article-26631.r31">[31]</xref><xref ref-type="bibr" rid="article-26631.r32">[32]</xref><xref ref-type="bibr" rid="article-26631.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Paraneoplastic Cerebellar Degeneration</bold> is predominant in 15% of cases of PEM. It can be relatively isolated to the cerebellum when associated with Anti-Yo and Anti-Tr antibodies but can be associated with any of the other mentioned paraneoplastic antibodies when present as a part of PEM. Cases usually present with dizziness, closely followed by motor gait ataxia, oscillopsia, diplopia, dysphagia, and dysarthria.<xref ref-type="bibr" rid="article-26631.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Myelitis</bold> can take place with PEM as well, in the form of either neuronal degeneration, inflammatory infiltrates, necrotizing myelitis, or demyelination. It is known to most commonly involve the dorsal root ganglia. Subsequently, patients show a predominant Subacute Sensory Neuronopathy (SSN) which is distinct from the common peripheral neuropathy in early involving the proximal sensory areas, usually asymmetrically and starting with the loss of vibration and proprioception, which can progress to sensory ataxia. In addition, it can also involve the anterior horn cells causing paraneoplastic motor neuron syndromes, which usually present as spastic paresis that differs from typical ALS by the involvement of other CNS areas and functions, while other times Subacute Motor Neuronopathy is seen leading to asymmetric flaccid weakness.<xref ref-type="bibr" rid="article-26631.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Paraneoplastic Stiff Person Syndrome</bold> represents about 5% of all SPS cases, with tumors typically arising from breast, lung, colon, thymus, and Hodgkin's lymphoma. It is believed to occur through loss of GABA inhibition of the interneurons at the brainstem and spinal cord levels. It presents as progressive muscle stiffness or rigidity, mainly affecting the proximal and axial muscle groups especially of the neck and upper limbs, and is associated with muscle spasms which are exacerbated by noise, touch, or emotions.<xref ref-type="bibr" rid="article-26631.r34">[34]</xref>&#x000a0;It is often linked with anti-amphiphysin antibodies.<xref ref-type="bibr" rid="article-26631.r35">[35]</xref><xref ref-type="bibr" rid="article-26631.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Autonomic Dysfunction</bold> occurs in 10% to 30% of cases of PEM when the pathology affects the autonomic centers and can predominate in the form of orthostatic hypotension, pupillary defects, gastroparesis, intestinal disturbances, neurogenic bladder, and impotence.</p>
          </list-item>
          <list-item>
            <p><bold>Paraneoplastic Neuromyelitis Optical Spectrum Disorders</bold> (NMOSD) occurs in 4-5% of AQP4 antibody-positive cases of NMOSD and 15% of cases among the older population. Reported neoplasms associated with this syndrome include breast, lung, nasopharyngeal, genitourinary, thyroid cancers, and thymoma.&#x000a0;</p>
          </list-item>
        </list>
        <p>Involved CNS regions are usually detected by completing a detailed neurologic examination, focusing on regions of the CNS identified as involved by clinical history. This exam can verify the level of neurologic involvement (e.g. &#x02013; cortical region(s), diencephalon, basal ganglia, cerebellum, brainstem, spinal cord), Historical data on cognitive dysfunction can be tested with focused cognitive testing at the time of initial neurological exam, to address regional or more generalized cortical or subcortical encephalopathy.&#x000a0;</p>
      </sec>
      <sec id="article-26631.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>CSF &#x00026; Serum Antibodies</bold>
</p>
        <p>PNS antibodies are detected before, during, or years after diagnosis of a neurological syndrome.<xref ref-type="bibr" rid="article-26631.r37">[37]</xref></p>
        <p>Simultaneous testing of both serum and CSF for antibodies should be done to maximize detection rates.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref><xref ref-type="bibr" rid="article-26631.r19">[19]</xref>&#x000a0;CSF antibody testing has a higher specificity for identifying the antibody associated with the paraneoplastic syndrome because the serum might have multiple antibodies that are not directly associated with the paraneoplastic syndrome.</p>
        <p>Basic panel diagnostics study for the following antibodies is recommended: Hu, Ri, Yo, Tr, Ma, CRMP5, and amphiphysin. However, it&#x000a0;must be noted that various antibodies might be associated with the same paraneoplastic syndrome, and one antibody may be associated with different syndromes. Several antibodies may be found simultaneously in the same patient with SCLC&#x000a0;or thymoma.<xref ref-type="bibr" rid="article-26631.r38">[38]</xref><xref ref-type="bibr" rid="article-26631.r39">[39]</xref><xref ref-type="bibr" rid="article-26631.r40">[40]</xref><xref ref-type="bibr" rid="article-26631.r41">[41]</xref><xref ref-type="bibr" rid="article-26631.r42">[42]</xref><xref ref-type="bibr" rid="article-26631.r43">[43]</xref><xref ref-type="bibr" rid="article-26631.r44">[44]</xref><xref ref-type="bibr" rid="article-26631.r45">[45]</xref><xref ref-type="bibr" rid="article-26631.r46">[46]</xref></p>
        <p>Higher titers of paraneoplastic antibodies correlate well with the diagnosis as well as the level of differentiation of the tumor.<xref ref-type="bibr" rid="article-26631.r37">[37]</xref></p>
        <p>In general, CSF analysis shows mild pleocytosis, i.e., 30 to 40 white blood cells per cubic millimeter, slightly elevated protein level 50 to 100 mg/dL, elevated IgG level, and presence of oligoclonal bands. Cytologic&#x000a0;testing&#x000a0;should be&#x000a0;performed on CSF samples to exclude meningeal metastasis of cancer.<xref ref-type="bibr" rid="article-26631.r14">[14]</xref></p>
        <p>
<bold>Electroencephalogram (EEG)</bold>
</p>
        <p>EEG in PNS often shows nonspecific findings like generalized slowing and periodic lateralized epileptiform discharges (PLEDs). However, PNS patients with anti-neuronal antibodies are significantly more likely to have observed frontal intermittent rhythmic delta activity (FIRDA) relative to control patients without the paraneoplastic disease.&#x000a0; &#x000a0;A characteristic finding also is the presence of epileptiform activity over temporal regions in limbic encephalitis. In addition, EEG helps to exclude subclinical seizures or nonconvulsive status epilepticus, the latter present at increased frequency in patients with PNS. &#x000a0;While typically not specific for paraneoplastic neurological syndromes, the presence of simultaneous rhythmic delta waves with beta frequency activity producing a &#x0201c;delta brush&#x0201d; pattern is specific for NMDAR Ab positive encephalitis among paraneoplastic conditions, even though it can also be seen rarely in non-paraneoplastic disease.<xref ref-type="bibr" rid="article-26631.r47">[47]</xref><xref ref-type="bibr" rid="article-26631.r48">[48]</xref>&#x000a0;A link between mesial temporal lobe epilepsy and the presence of VGKC antibodies has also been reported.<xref ref-type="bibr" rid="article-26631.r49">[49]</xref></p>
        <p>
<bold>Imaging&#x000a0;</bold>
</p>
        <p>Increased MRI signal in T2 weighted/FLAIR imaging in bilateral medial temporal lobes supports the diagnosis of definite limbic encephalitis in the appropriate clinical context. MRI is also used to exclude stroke or metastatic disease. FDG-PET CT shows hypermetabolism in the medial temporal lobes and is more sensitive than MRI in the diagnosis and evaluation of&#x000a0;paraneoplastic limbic encephalitis.<xref ref-type="bibr" rid="article-26631.r50">[50]</xref></p>
        <p>Both extensive optic neuritis identified on gadolinium-enhanced brain MRI and enhancing T1 and/or T2 hyperintense longitudinally extensive transverse myelitis (LETM) on spinal cord MRI, the latter by definition extending more than 3 vertebral segments, have been identified in paraneoplastic and non-paraneoplastic forms of NMOSD and MOG antibody-positive myelitis.<xref ref-type="bibr" rid="article-26631.r51">[51]</xref><xref ref-type="bibr" rid="article-26631.r52">[52]</xref><xref ref-type="bibr" rid="article-26631.r53">[53]</xref></p>
        <p>
<bold>Cancer Screening</bold>
</p>
        <p>Since detecting the tumor is essential for treatment, a Whole-body PET scan is the best screening method for localizing occult cancer.<xref ref-type="bibr" rid="article-26631.r14">[14]</xref></p>
        <p>The likelihood of a tumor being revealed by a whole-body CT scan or FDG-PET is more than 95% when the patient presents with a classical PNS like PEM and a well-characterized onconeural antibody.<xref ref-type="bibr" rid="article-26631.r11">[11]</xref></p>
        <p>The 2010 task force recommended repeat cancer screening 3 to 6 months after the initial evaluation, followed by screening every 6 months for up to 4 years if testing remains unrevealing.&#x000a0; Also, if an identified cancer is not consistent with the PNS or the identified antibody, a continued search for another&#x000a0;cancer should be considered.<xref ref-type="bibr" rid="article-26631.r54">[54]</xref></p>
        <p>Sometimes the tumor may never be identified as a result of immune-mediated eradication of tumor cells.<xref ref-type="bibr" rid="article-26631.r18">[18]</xref></p>
      </sec>
      <sec id="article-26631.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Neuronal damage often progresses rapidly in PNS. Treatment should be started immediately without waiting for antibody analysis results.</p>
        <p><bold>Tumor removal: </bold>Once the tumor is identified, a prompt, complete removal is recommended so as to eliminate the ectopically produced antigen present on it.</p>
        <p><bold>Immunosuppression/Immunomodulation: </bold>Classic paraneoplastic encephalitis is hard to treat because the neuronal damage is cell-mediated. Hence, antibody directed therapies like IVIG and plasmapheresis are ineffective. On the other hand, T cell-directed therapies such as cyclophosphamide, rituximab, steroids, mycophenolate mofetil, and tacrolimus have been shown to have a modest effect in some cases.</p>
        <p>Therapy in PNS is often delayed, and substantial irreversible neuronal cell damage has already occurred at the time of presentation.&#x000a0; After&#x000a0;3 to 6 months of therapy, repeat brain imaging is recommended.&#x000a0; If the disease has progressed, immunotherapy should be stopped.<xref ref-type="bibr" rid="article-26631.r14">[14]</xref><xref ref-type="bibr" rid="article-26631.r55">[55]</xref><xref ref-type="bibr" rid="article-26631.r56">[56]</xref></p>
        <p><bold>Symptomatic:</bold> Anti-epileptic drugs are to be used for seizures. Muscle rigidity and spasms can be managed with muscle relaxants such as baclofen, tizanidine, and benzodiazepines.</p>
        <p><bold>Stop</bold> immune checkpoint inhibitors promptly if suspected to be causing PNS.<xref ref-type="bibr" rid="article-26631.r19">[19]</xref></p>
      </sec>
      <sec id="article-26631.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Infectious etiologies</bold>; viral [herpes viruses, hepatitis C, HIV, Varicella zoster virus, Ebstein Barr virus], bacterial [Listeria, Rickettsia, Tropheryma whipplei, Bartonella, Mycoplasma], spirochetal [syphilis, Lyme, leptospirosis], fungal [cryptococcus, coccidioidomycosis, histoplasmosis, aspergillosis], TB, and CJD should be considered in the differential diagnosis of paraneoplastic disease.</p>
        <p><bold>Toxic/metabolic</bold>; Alcohol, ketamine or phencyclidine ingestion, intrathecal chemotherapy or radiotherapy effect, carbon monoxide, Wernicke's encephalopathy, NMS-neuroleptic malignant syndrome.</p>
        <p><bold>Vascular disorders</bold>; posterior reversible encephalopathy syndrome, angiitis of the CNS, Behcet's disease, Susac&#x02019;s syndrome.</p>
        <p><bold>Neoplastic disorders</bold>; leptomeningeal or epidural metastasis, diffuse glioma, CNS lymphoma.</p>
        <p><bold>Demyelinating/Inflammatory disorders</bold>; multiple sclerosis, neurosarcoidosis, NMO-neuromyelitis optica, ADEM [acute disseminated encephalomyelitis], neurosarcoidosis, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, Bickerstaff encephalitis.</p>
        <p><bold>Neurodegenerative dementias</bold>; Alzheimer's disease, frontotemporal dementia, and vascular dementia, dementia with Lewy bodies.</p>
        <p><bold>Psychiatric diseases</bold>; schizophrenia, bipolar disorder</p>
        <p><bold>Inherited/metabolic disorders</bold>; mitochondrial encephalopathies, Hashimoto's encephalitis<xref ref-type="bibr" rid="article-26631.r30">[30]</xref></p>
      </sec>
      <sec id="article-26631.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>For classic paraneoplastic syndromes, the prognosis is overall poor, with the exception of young males with testicular cancer and anti-Ma-2 antibodies who are known to have a better prognosis. Children with anti-Hu encephalomyelitis are&#x000a0;exceptionally treatment-resistant.<xref ref-type="bibr" rid="article-26631.r5">[5]</xref><xref ref-type="bibr" rid="article-26631.r57">[57]</xref>&#x000a0;However, for patients with an extracellular epitope targeted antibodies, and for many patients with intracellular neuromuscular junction targeted antibodies, both direct suppression of the paraneoplastic antibodies and prompt removal of the tumor can produce significantly better outcomes.</p>
        <p>Factors associated with poor neurological outcomes&#x000a0;include delay in administering immunotherapy, need for mechanical ventilation, intrathecal inflammation, and need for tracheostomy.<xref ref-type="bibr" rid="article-26631.r58">[58]</xref></p>
        <p>The main causes of death are brainstem or autonomic dysfunction, severe pneumonia, multiple organ dysfunction syndromes, and refractory status epilepticus.<xref ref-type="bibr" rid="article-26631.r17">[17]</xref></p>
        <p>Some patients may develop a second paraneoplastic syndrome after recovering stabilizing from the first, indicating cancer relapse or the presence of second cancer.<xref ref-type="bibr" rid="article-26631.r59">[59]</xref></p>
        <p>Limbic encephalitis from immune checkpoint inhibitors&#x000a0;is secondary to cancer treatment and usually responds well to&#x000a0;drug cessation and rapid initiation of steroids.<xref ref-type="bibr" rid="article-26631.r19">[19]</xref></p>
      </sec>
      <sec id="article-26631.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The most common reasons for ICU care include altered mental status requiring intubation, status epilepticus/refractory status epilepticus, severe hyperkinetic movements, respiratory failure, autonomic dysfunction, and increased intracranial pressure.</p>
      </sec>
      <sec id="article-26631.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with known cancer or being treated with immune checkpoint inhibitors should seek immediate medical attention if they develop any neurological symptoms.</p>
      </sec>
      <sec id="article-26631.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Classic paraneoplastic encephalomyelitis belongs to a group of neurological syndromes associated with antibodies against intracellular neuronal proteins that are invariably cancer-related.</p>
          </list-item>
          <list-item>
            <p>Non-classical paraneoplastic encephalomyelitis is directly produced by surface epitope or intracellular neuromuscular junction epitope-targeted antibodies, similar to those producing primary autoimmune encephalomyelitis.</p>
          </list-item>
          <list-item>
            <p>PEM&#x000a0;can be seen with&#x000a0;multiple cancers&#x000a0;(i.e. - small cell lung cancer, thymoma, testicular cancer) as well as with the use of immune checkpoint inhibitors (i.e. - pembrolizumab).</p>
          </list-item>
          <list-item>
            <p>For all PEM types, the&#x000a0;underlying trigger is thought to be ectopically presented neural antigens on tumor cells causing&#x000a0;either a cell-mediated or antibody-mediated immune attack of the central nervous system.</p>
          </list-item>
          <list-item>
            <p>Common presentations of PEM include limbic encephalitis, brainstem encephalitis, cerebellar degeneration, myelitis, stiff-person syndrome, NMOSD, and autonomic dysfunction.</p>
          </list-item>
          <list-item>
            <p>Recommended workup includes antibody panel testing of serum and CSF, MRI/FDG-PET CT scan, EEG, and cancer screening.</p>
          </list-item>
          <list-item>
            <p>PEM&#x000a0;is a diagnosis of exclusion and extensive&#x000a0;evaluations are often needed to&#x000a0;exclude other causes of encephalomyelitis.</p>
          </list-item>
          <list-item>
            <p>Treatment involves prompt tumor removal, and use of T cell-directed therapies like cyclophosphamide, steroids, and tacrolimus for classic PEM, and IVIg, plasmapheresis, or steroids for non-classic PEM.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The overall prognosis varies, depending on the cancer type, paraneoplastic marker antibody, and type of immune response produced in the paraneoplastic disease.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26631.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early clinical suspicion for the disease entity can lead to rapid diagnosis and better outcomes. Oncologists, neurologists, psychiatrists, intensivists, hospitalists, physical medicine/rehabilitation physicians, nurses, physical therapists, and occupational therapists&#x000a0;should be involved early in the patient's care, to speed diagnosis and therapy initiation. Patient education about the condition is important to ensure compliance with therapies provided. Palliative care should be involved in cases where&#x000a0;the prognosis is poor.</p>
      </sec>
      <sec id="article-26631.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26631&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26631">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/paraneoplastic-encephalomyelitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26631">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26631/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26631">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26631.s17">
        <title>References</title>
        <ref id="article-26631.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gultekin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic neurologic syndromes: pathogenesis and physiopathology.</article-title>
            <source>Brain Pathol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-84</page-range>
            <pub-id pub-id-type="pmid">10219745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinmaz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Brilot</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system.</article-title>
            <source>J Neuroinflammation</source>
            <year>2016</year>
            <month>Aug</month>
            <day>30</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>219</fpage>
            <pub-id pub-id-type="pmid">27577085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delattre</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giometto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smitt</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Vedeler</surname>
                <given-names>Ch</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Voltz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Recommended diagnostic criteria for paraneoplastic neurological syndromes.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>75</volume>
            <issue>8</issue>
            <fpage>1135</fpage>
            <page-range>1135-40</page-range>
            <pub-id pub-id-type="pmid">15258215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Balu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benseler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bien</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Cellucci</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Geschwind</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ftberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reindl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rost&#x000e1;sy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venkatesan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wandinger</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A clinical approach to diagnosis of autoimmune encephalitis.</article-title>
            <source>Lancet Neurol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>391</fpage>
            <page-range>391-404</page-range>
            <pub-id pub-id-type="pmid">26906964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Significance of Autoantibodies in Autoimmune Encephalitis in Relation to Antigen Localization: An Outline of Frequently Reported Autoantibodies with a Non-Systematic Review.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Jul</month>
            <day>13</day>
            <volume>21</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">32668637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trenevska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Banham</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Antibodies against Intracellular Tumor Antigens.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>1001</fpage>
            <pub-id pub-id-type="pmid">28868054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weishaupt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cola&#x000e7;o</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Toyka</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Geis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Human Stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats.</article-title>
            <source>Exp Neurol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>239</volume>
            <fpage>202</fpage>
            <page-range>202-9</page-range>
            <pub-id pub-id-type="pmid">23099416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iorio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Damato</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Spagni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Della Marca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vollono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Campetella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Monte</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Evoli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology.</article-title>
            <source>Eur J Neurol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>2062</fpage>
            <page-range>2062-2071</page-range>
            <pub-id pub-id-type="pmid">32412135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.</article-title>
            <source>Physiol Rev</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>97</volume>
            <issue>2</issue>
            <fpage>839</fpage>
            <page-range>839-887</page-range>
            <pub-id pub-id-type="pmid">28298428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Antibody-Mediated Encephalitis.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>378</volume>
            <issue>9</issue>
            <fpage>840</fpage>
            <page-range>840-851</page-range>
            <pub-id pub-id-type="pmid">29490181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vogrig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;iz-Castrillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desestret</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Joubert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>1756286420932797</fpage>
            <pub-id pub-id-type="pmid">32636932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>535</fpage>
            <page-range>535-548</page-range>
            <pub-id pub-id-type="pmid">30867573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic Diseases of the Central Nervous System.</article-title>
            <source>F1000Res</source>
            <year>2020</year>
            <volume>9</volume>
            <pub-id pub-id-type="pmid">32194943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darnell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic syndromes involving the nervous system.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Oct</month>
            <day>16</day>
            <volume>349</volume>
            <issue>16</issue>
            <fpage>1543</fpage>
            <page-range>1543-54</page-range>
            <pub-id pub-id-type="pmid">14561798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanikannan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sirisha</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uppin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Jabeen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kandadai</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sundaram</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raghunadharao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Borgohain</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Incidence and spectrum of paraneoplastic neurological syndromes: single center study.</article-title>
            <source>J Neurooncol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>197</fpage>
            <page-range>197-206</page-range>
            <pub-id pub-id-type="pmid">26307447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic neurological syndromes.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2007</year>
            <month>May</month>
            <day>04</day>
            <volume>2</volume>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">17480225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>59</fpage>
            <page-range>59-72</page-range>
            <pub-id pub-id-type="pmid">1312211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darnell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Jan</month>
            <day>02</day>
            <volume>341</volume>
            <issue>8836</issue>
            <fpage>21</fpage>
            <page-range>21-2</page-range>
            <pub-id pub-id-type="pmid">8093269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis associated with lung cancer.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>6792</fpage>
            <pub-id pub-id-type="pmid">29717222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shams'ili</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grefkens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Leeuw</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van den Bent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hooijkaas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van der Holt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vecht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.</article-title>
            <source>Brain</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>126</volume>
            <issue>Pt 6</issue>
            <fpage>1409</fpage>
            <page-range>1409-18</page-range>
            <pub-id pub-id-type="pmid">12764061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popkirov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ayzenberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Denno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rieckhoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radzimski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hans</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roghmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Noldus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bien</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Skodda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wellmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>St&#x000f6;cker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Krogias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schlegel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Komorowski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miske</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kleiter</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis.</article-title>
            <source>Acta Neuropathol Commun</source>
            <year>2017</year>
            <month>May</month>
            <day>29</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <pub-id pub-id-type="pmid">28554330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandel-Brehm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kryzer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>O'Donovan</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sample</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Zorn</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bledsoe</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pleasure</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>DeRisi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>04</day>
            <volume>381</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-54</page-range>
            <pub-id pub-id-type="pmid">31269365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bien</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;nzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dargvainiene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dogan-Onugoren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woermann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Strickler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Co-occurrence of antibodies against dipeptidyl-peptidase-like protein-6 and aquaporin-4 during a case of paraneoplastic encephalitis.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>197</volume>
            <fpage>106093</fpage>
            <pub-id pub-id-type="pmid">32702576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic autoimmune movement disorders.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>44</volume>
            <fpage>106</fpage>
            <page-range>106-109</page-range>
            <pub-id pub-id-type="pmid">29097081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baehring</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bannykh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma.</article-title>
            <source>Acta Neuropathol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-43</page-range>
            <pub-id pub-id-type="pmid">19680671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barry</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Cotter</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment.</article-title>
            <source>BJPsych Bull</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-23</page-range>
            <pub-id pub-id-type="pmid">26191419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Urich</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Encephalomyelitis with carcinoma.</article-title>
            <source>Brain</source>
            <year>1965</year>
            <month>Sep</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>449</fpage>
            <page-range>449-64</page-range>
            <pub-id pub-id-type="pmid">5890519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grativvol</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cavalcante</surname>
                <given-names>WCP</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>LHM</given-names>
              </name>
              <name>
                <surname>Nitrini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simabukuro</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.</article-title>
            <source>Curr Oncol Rep</source>
            <year>2018</year>
            <month>Nov</month>
            <day>10</day>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>92</fpage>
            <pub-id pub-id-type="pmid">30415318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voltz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gultekin</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gerstner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eichen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Jun</month>
            <day>10</day>
            <volume>340</volume>
            <issue>23</issue>
            <fpage>1788</fpage>
            <page-range>1788-95</page-range>
            <pub-id pub-id-type="pmid">10362822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Damian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Trismus caused by paraneoplastic brainstem encephalitis.</article-title>
            <source>Pract Neurol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-150</page-range>
            <pub-id pub-id-type="pmid">29440480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moragas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Y&#x000e9;lamos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maj&#x000f3;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Viladrich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arbizu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Rhombencephalitis: a series of 97 patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>256</fpage>
            <page-range>256-261</page-range>
            <pub-id pub-id-type="pmid">21694648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ebers</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma.</article-title>
            <source>Neurology</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>788</fpage>
            <page-range>788-91</page-range>
            <pub-id pub-id-type="pmid">6539443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bruna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stourac</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vigliani</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Giometto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Psimaras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Voltz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Anti-Hu-associated brainstem encephalitis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>404</fpage>
            <page-range>404-7</page-range>
            <pub-id pub-id-type="pmid">19015226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarva</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ullah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Severt</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2016</year>
            <volume>6</volume>
            <fpage>340</fpage>
            <pub-id pub-id-type="pmid">26989571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murinson</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Guarnaccia</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>Dec</month>
            <day>09</day>
            <volume>71</volume>
            <issue>24</issue>
            <fpage>1955</fpage>
            <page-range>1955-8</page-range>
            <pub-id pub-id-type="pmid">18971449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Abassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Villemarette-Pittman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>SPS: Understanding the complexity.</article-title>
            <source>J Neurol Sci</source>
            <year>2019</year>
            <month>Sep</month>
            <day>15</day>
            <volume>404</volume>
            <fpage>137</fpage>
            <page-range>137-149</page-range>
            <pub-id pub-id-type="pmid">31377632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seluk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taliansky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yonath</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gilburd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amital</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shoenfeld</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kivity</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.</article-title>
            <source>Clin Immunol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>199</volume>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">30543927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drlicek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bogliun</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Casati</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kolig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liszka-Setinek</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Marzorati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wondrusch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cavaletti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients.</article-title>
            <source>J Neurol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>244</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-9</page-range>
            <pub-id pub-id-type="pmid">9120501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bataller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stacey</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.</article-title>
            <source>Neurology</source>
            <year>2004</year>
            <month>Mar</month>
            <day>09</day>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>778</fpage>
            <page-range>778-82</page-range>
            <pub-id pub-id-type="pmid">15007130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Re&#x000f1;&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tora</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malats</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cardenal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vi&#x000f1;olas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garcia del Muro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vadell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Rosell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>2866</fpage>
            <page-range>2866-72</page-range>
            <pub-id pub-id-type="pmid">9256130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Furneaux</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Gralla</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kris</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.</article-title>
            <source>Ann Neurol</source>
            <year>1990</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>544</fpage>
            <page-range>544-52</page-range>
            <pub-id pub-id-type="pmid">2163235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kryzer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome.</article-title>
            <source>Ann Neurol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-9</page-range>
            <pub-id pub-id-type="pmid">15468074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond.</article-title>
            <source>Arch Neurol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>10</issue>
            <fpage>1282</fpage>
            <page-range>1282-9</page-range>
            <pub-id pub-id-type="pmid">21670387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padda</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Antonicelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riess</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shrager</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Korst</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Detterbeck</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burt</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Wakelee</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Badve</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.</article-title>
            <source>J Thorac Oncol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>436</fpage>
            <page-range>436-446</page-range>
            <pub-id pub-id-type="pmid">29191778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A rare thymoma case with seven paraneoplastic syndromes.</article-title>
            <source>Int J Clin Exp Med</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>19517</fpage>
            <page-range>19517-23</page-range>
            <pub-id pub-id-type="pmid">26770603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Atay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McFadden</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Stamnes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lechtholz-Zey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wightman</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Detterbeck</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>160</volume>
            <issue>1</issue>
            <fpage>306</fpage>
            <page-range>306-314.e14</page-range>
            <pub-id pub-id-type="pmid">31982129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baysal-Kirac</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tuzun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Altindag</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ekizoglu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kinay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bilgic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tekturk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baykan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Are There Any Specific EEG Findings in Autoimmune Epilepsies?</article-title>
            <source>Clin EEG Neurosci</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>224</fpage>
            <page-range>224-34</page-range>
            <pub-id pub-id-type="pmid">26240088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baykan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gungor Tuncer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vanli-Yavuz</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Baysal Kirac</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gundogdu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bebek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gurses</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Altindag</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tuzun</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Delta Brush Pattern Is Not Unique to NMDAR Encephalitis: Evaluation of Two Independent Long-Term EEG Cohorts.</article-title>
            <source>Clin EEG Neurosci</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>278</fpage>
            <page-range>278-284</page-range>
            <pub-id pub-id-type="pmid">29161898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanli-Yavuz</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Erdag</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tuzun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ekizoglu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baysal-Kirac</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ulusoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gundogdu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sencer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sencer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kucukali</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Bebek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gurses</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gokyigit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baykan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>87</volume>
            <issue>7</issue>
            <fpage>684</fpage>
            <page-range>684-92</page-range>
            <pub-id pub-id-type="pmid">27151964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alavi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.</article-title>
            <source>Mol Imaging Biol</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-7</page-range>
            <pub-id pub-id-type="pmid">18297363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic neuromyelitis optica spectrum disorder associated with breast cancer.</article-title>
            <source>Clin Interv Aging</source>
            <year>2019</year>
            <volume>14</volume>
            <fpage>1039</fpage>
            <page-range>1039-1044</page-range>
            <pub-id pub-id-type="pmid">31239653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernard-Valnet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cobo-Calvo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siegfried</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marasescu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ellie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Uro-Coste</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marignier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brassat</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>31</volume>
            <fpage>97</fpage>
            <page-range>97-100</page-range>
            <pub-id pub-id-type="pmid">30954932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flanagan</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weinshenker</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Krecke</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Matiello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keegan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Mokri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aksamit</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues.</article-title>
            <source>Neurology</source>
            <year>2011</year>
            <month>Jun</month>
            <day>14</day>
            <volume>76</volume>
            <issue>24</issue>
            <fpage>2089</fpage>
            <page-range>2089-95</page-range>
            <pub-id pub-id-type="pmid">21670438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Soffietti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gilhus</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Giometto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tanasescu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vedeler</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Voltz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>JJ</given-names>
              </name>
              <collab>European Federation of Neurological Societies</collab>
            </person-group>
            <article-title>Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.</article-title>
            <source>Eur J Neurol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-e3</page-range>
            <pub-id pub-id-type="pmid">20880069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current Therapies for Paraneoplastic Neurologic Syndromes.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-77</page-range>
            <pub-id pub-id-type="pmid">12521564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vernino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kimmel</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Immunomodulatory treatment trial for paraneoplastic neurological disorders.</article-title>
            <source>Neuro Oncol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-62</page-range>
            <pub-id pub-id-type="pmid">14769141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Didelot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karantoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ville</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ducray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deiva</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pichit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cavillon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rogemond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>DeLattre</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Tardieu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Jun</month>
            <day>11</day>
            <volume>80</volume>
            <issue>24</issue>
            <fpage>2226</fpage>
            <page-range>2226-32</page-range>
            <pub-id pub-id-type="pmid">23658383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Montmollin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Demeret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brul&#x000e9;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dailler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lerolle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Navellou</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Schwebel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engrand</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tonnelier</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Maury</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ruckly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rogemond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Magalhaes</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Sharshar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Timsit</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sonneville</surname>
                <given-names>R</given-names>
              </name>
              <collab>ENCEPHALITICA Study Group &#x02021;</collab>
            </person-group>
            <article-title>Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>195</volume>
            <issue>4</issue>
            <fpage>491</fpage>
            <page-range>491-499</page-range>
            <pub-id pub-id-type="pmid">27552490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26631.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ducray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vigliani</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rogemond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Delayed onset of a second paraneoplastic neurological syndrome in eight patients.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>81</volume>
            <issue>8</issue>
            <fpage>937</fpage>
            <page-range>937-9</page-range>
            <pub-id pub-id-type="pmid">20562403</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
